Thailand Cannabis Legalization: Laws, Timeline & Current Status

Executive Summary

Thailand became the first Asian nation to decriminalize cannabis in June 2022, removing the plant from its Category 5 narcotics list and sparking a brief period of unregulated commercialization. The move created a legal gray zone that allowed thousands of dispensaries to open across Bangkok, Chiang Mai, Phuket, and other tourist destinations. However, the initial decriminalization lacked comprehensive regulatory frameworks, leading to concerns about recreational use, public health, and social order. By late 2024, Thailand's government began implementing stricter controls, culminating in new regulations that took effect in 2025 and continue to evolve through 2026. The current legal framework permits medical and wellness use of cannabis with THC content below 0.2 percent, while recreational use remains prohibited. Enforcement has intensified, with authorities closing unlicensed dispensaries and prosecuting violations. The regulatory shift has created uncertainty for the estimated 6,000-9,000 cannabis businesses that emerged during the permissive period, while establishing clearer pathways for legitimate medical cannabis operations. Thailand's experience represents a cautionary tale of rapid liberalization without adequate preparation, offering lessons for other jurisdictions considering cannabis policy reform.

Why This Matters

Thailand's cannabis policy directly affects millions of stakeholders across Southeast Asia and the global cannabis industry. The country's 70 million residents navigate evolving rules that impact medical access, criminal liability, and economic opportunity. An estimated 1.2 million Thais registered to grow cannabis at home during the permissive period from June 2022 through mid-2024, according to Thailand's Food and Drug Administration. The tourism sector, which contributed $28 billion to Thailand's economy in 2025, saw cannabis emerge as a significant draw for international visitors, particularly from markets where the plant remains illegal. The financial stakes are substantial. Industry analysts estimated Thailand's cannabis market reached $1.2 billion in 2024 before regulatory tightening began. Thousands of entrepreneurs invested capital in dispensaries, cultivation facilities, and cannabis-infused product manufacturing. The regulatory reversal has created losses estimated at $400-600 million as businesses closed or pivoted operations. International cannabis companies including Canadian licensed producers and U.S. multi-state operators had begun exploring Thai market entry, viewing the country as a potential gateway to broader Asian markets. For patients, the policy changes affect access to cannabis-based treatments for chronic pain, epilepsy, chemotherapy side effects, and other conditions. Thailand's medical cannabis program registered approximately 180,000 patients by early 2025, though enforcement of the recreational ban has created confusion about legal access pathways. The regulatory uncertainty has also impacted research institutions, as Thai universities had begun cannabis research programs that now face funding and legal clarity challenges.

Background and History: From Prohibition to Liberalization and Back

Thailand's relationship with cannabis spans centuries, from traditional medicine to strict prohibition to Asia's most dramatic modern liberalization experiment.

Traditional Use and Colonial-Era Prohibition (Pre-1979)

Cannabis grew naturally across Thailand for centuries and held an established place in traditional Thai medicine. Practitioners used cannabis leaves and flowers to treat pain, improve appetite, and address digestive ailments. The plant appeared in traditional pharmacopeias alongside other herbal remedies. However, Thailand signed the 1961 United Nations Single Convention on Narcotic Drugs, which classified cannabis as a controlled substance. In 1979, Thailand enacted the Narcotics Act B.E. 2522, placing cannabis in Category 5—the strictest classification—alongside heroin and methamphetamine. Possession became punishable by up to five years imprisonment and fines up to 100,000 baht ($2,800).

Medical Cannabis Pilot Programs (2018-2022)

Thailand began reconsidering cannabis policy in 2018 as global attitudes shifted and evidence mounted for medical applications. On December 25, 2018, Thailand's National Legislative Assembly amended the Narcotics Act to allow medical cannabis and kratom research. The amendment, which took effect February 18, 2019, made Thailand the first Southeast Asian nation to legalize medical cannabis. The Government Pharmaceutical Organization began producing cannabis oil for medical trials in 2020. The medical program initially operated under strict controls. Only government hospitals could prescribe cannabis products, and patients required specific qualifying conditions including chemotherapy side effects, epilepsy, and chronic pain. The program registered 4,800 patients in its first year. In January 2021, Thailand's FDA approved home cultivation of up to six cannabis plants for medical purposes, requiring registration through the government's Plook Ganja mobile application.

Full Decriminalization (June 2022)

On June 9, 2022, Thailand's Ministry of Public Health removed cannabis and hemp from the Category 5 narcotics list entirely. Health Minister Anutin Charnvirakul, leader of the Bhumjaithai Party, championed the move as an economic development opportunity for Thai farmers. The delisting meant cannabis possession and cultivation were no longer criminal offenses. The government maintained that recreational use remained illegal under the Public Health Act, but enforcement mechanisms were unclear. The decriminalization created an immediate commercial boom. Dispensaries opened across Bangkok, Pattaya, Chiang Mai, and Phuket within weeks. Entrepreneurs sold cannabis flowers, pre-rolled joints, edibles, and beverages with minimal oversight. By August 2022, an estimated 3,000 dispensaries operated nationwide. The FDA registered more than 1.1 million individuals and 6,000 businesses for cannabis cultivation and sales by December 2022.

Growing Concerns and Political Backlash (2023-2024)

The permissive environment generated public health and social concerns. Reports emerged of minors accessing cannabis, tourists consuming cannabis in public spaces, and impaired driving incidents. Conservative political factions and public health advocates criticized the lack of regulation. In May 2023, the Move Forward Party, which won the most parliamentary seats in national elections, pledged to re-criminalize recreational cannabis use. The party's leader, Pita Limjaroenrat, called the 2022 decriminalization "premature and chaotic." Political negotiations delayed immediate action, but momentum built for regulatory tightening. In January 2024, the Ministry of Public Health proposed draft regulations limiting THC content in consumer products to 0.2 percent and restricting sales to licensed medical dispensaries. The proposal generated fierce debate between business interests and public health advocates.

Regulatory Tightening (2025-Present)

In March 2025, Thailand's parliament passed the Cannabis and Hemp Control Act B.E. 2568, establishing comprehensive regulations. The law took effect June 1, 2025, and created a licensing system for cultivation, processing, and distribution. Key provisions included: - THC content limits of 0.2 percent for consumer products - Mandatory licensing for all cannabis businesses - Prohibition of recreational use, defined as consumption for non-medical purposes - Restrictions on advertising and public consumption - Age restrictions limiting sales to individuals 20 and older The Ministry of Public Health began enforcement in July 2025, inspecting dispensaries and revoking licenses for non-compliance. By September 2025, authorities had closed approximately 2,400 unlicensed dispensaries and filed criminal charges against 340 operators for violating the new regulations. The crackdown continued through 2026, with police conducting raids in tourist areas including Bangkok's Khao San Road and Phuket's Patong Beach district.

Key Players

Ministry of Public Health

Thailand's Ministry of Public Health holds primary regulatory authority over cannabis policy. The ministry's Food and Drug Administration administers licensing, sets product standards, and conducts inspections. Health Minister Somsak Thepsutin, who took office in September 2023, has emphasized public health protection over commercial interests. The ministry operates the Thai Traditional and Alternative Medicine Development Department, which oversees medical cannabis prescriptions and patient registrations.

Bhumjaithai Party

The Bhumjaithai Party, Thailand's fourth-largest political party, championed cannabis liberalization as a signature policy. Party leader and former Health Minister Anutin Charnvirakul positioned cannabis as an agricultural opportunity for rural Thai farmers. The party's political fortunes became tied to cannabis policy, creating tension as public opinion shifted toward stricter controls. Bhumjaithai holds 71 seats in Thailand's 500-member House of Representatives and participates in the governing coalition as of 2026.

Move Forward Party

The Move Forward Party, which won 151 parliamentary seats in the May 2023 election, advocates re-criminalizing recreational cannabis. The party argues that the 2022 decriminalization lacked adequate preparation and created public health risks. Despite winning the most seats, Move Forward was blocked from forming a government and now serves as the opposition. The party continues pressing for stricter cannabis controls.

Thai Cannabis Industry Association

Industry stakeholders formed the Thai Cannabis Industry Association in late 2022 to advocate for business interests. The association represents dispensary owners, cultivators, and product manufacturers. The group has lobbied against strict THC limits and licensing requirements, arguing they threaten legitimate businesses. Association president Rattapon Sanrak estimated in April 2025 that regulatory changes would force 60-70 percent of existing cannabis businesses to close.

Thai FDA

The Food and Drug Administration, operating under the Ministry of Public Health, implements cannabis regulations at the operational level. The FDA maintains registries of licensed businesses, approves cannabis products, and conducts laboratory testing for THC content. The agency registered 8,900 cannabis-related businesses by March 2025, though only 3,200 received licenses under the new regulatory framework by September 2026.

Legal and Regulatory Framework

Thailand's current cannabis legal structure rests on the Cannabis and Hemp Control Act B.E. 2568, which replaced the permissive 2022 decriminalization with comprehensive regulations. The Narcotics Act B.E. 2522 (1979) remains Thailand's foundational drug control statute. Cannabis was removed from Category 5 of the narcotics schedule in June 2022, then effectively re-regulated through the Cannabis and Hemp Control Act rather than re-scheduling. This legislative approach created a separate regulatory regime for cannabis outside the traditional narcotics framework. The Cannabis and Hemp Control Act establishes several key legal standards: **THC Content Limits**: Products intended for consumption must contain no more than 0.2 percent THC by dry weight. This threshold applies to flowers, extracts, edibles, and beverages. Products exceeding 0.2 percent THC are classified as controlled substances requiring medical prescriptions. The 0.2 percent standard aligns with hemp definitions in the European Union and other jurisdictions. **Licensing Requirements**: The Act creates four license categories: cultivation, processing, distribution, and medical dispensing. Applicants must demonstrate proper facilities, quality control procedures, and compliance with good manufacturing practices. License fees range from 5,000 baht ($140) for small cultivators to 100,000 baht ($2,800) for large-scale processors. Licenses require annual renewal. **Permitted Uses**: The law authorizes cannabis use for medical treatment, traditional medicine, research, and industrial hemp applications. Medical use requires a prescription from a licensed physician. Traditional medicine practitioners registered with the Thai Traditional Medicine Council may also recommend cannabis products. Recreational use—defined as consumption without medical justification—remains prohibited and punishable by up to one year imprisonment and fines up to 20,000 baht ($560). **Advertising Restrictions**: The Act prohibits advertising cannabis products in ways that promote recreational use or target minors. Permitted advertising must include health warnings and cannot make unsubstantiated medical claims. Violations carry fines up to 500,000 baht ($14,000). **Public Consumption Bans**: Consuming cannabis in public spaces including parks, streets, restaurants, and transportation facilities is prohibited. Violators face fines up to 25,000 baht ($700). The ban aims to address concerns about secondhand smoke and public intoxication. **Home Cultivation**: Individuals may cultivate up to six cannabis plants at home for personal medical use after registering with the FDA through the Plook Ganja application. Home growers cannot sell their harvest and must comply with local zoning restrictions. Unregistered cultivation remains illegal. The Public Health Act B.E. 2535 (1992) provides additional enforcement authority. Section 25 prohibits actions that create public nuisances or health hazards, which authorities have interpreted to include public cannabis consumption and unlicensed sales. Enforcement responsibility is divided among multiple agencies. The FDA handles licensing and product standards. The Royal Thai Police enforce criminal provisions. Provincial health offices conduct local inspections. This multi-agency approach has created coordination challenges and inconsistent enforcement across regions.

Market and Business Implications

Thailand's regulatory reversal has devastated the cannabis industry that emerged during the 2022-2024 permissive period while creating opportunities for compliant medical operators. The Thai cannabis market reached an estimated $1.2 billion in 2024, according to Prohibition Partners, a cannabis market research firm. The market contracted sharply in 2025 as regulations took effect. Industry analysts project the legal market will stabilize at $400-600 million annually under the current regulatory framework, focused primarily on medical and wellness products. **Dispensary Closures**: Approximately 6,000-9,000 cannabis dispensaries operated in Thailand at the peak in early 2024. By September 2026, fewer than 2,000 remained open with proper licenses. The closures concentrated in tourist areas where recreational sales had been most prevalent. Bangkok's Khao San Road, which had 47 cannabis shops in March 2024, had only 8 licensed medical dispensaries by August 2026. Phuket saw similar contraction, with the number of cannabis retailers falling from approximately 380 to 65. **Cultivation Sector**: Thai farmers had planted an estimated 12,000 hectares of cannabis by mid-2024, according to the Ministry of Agriculture. Much of this cultivation targeted the recreational flower market. The shift to medical-only sales with THC limits has reduced demand for high-THC cultivars. Farmers are transitioning to hemp cultivation for industrial applications including textiles and construction materials, or abandoning cannabis entirely. Wholesale cannabis flower prices fell from 8,000-12,000 baht per kilogram ($225-$340) in early 2024 to 2,000-3,000 baht per kilogram ($56-$85) by mid-2026. **Product Manufacturing**: Companies producing cannabis-infused beverages, edibles, and cosmetics face reformulation requirements to meet the 0.2 percent THC limit. Many products marketed during the permissive period contained 5-10 percent THC or higher. Reformulation costs and reduced consumer appeal for low-THC products have forced numerous manufacturers out of business. The FDA approved 127 cannabis product formulations for legal sale as of September 2026, down from more than 800 products available in 2024. **International Investment**: Foreign cannabis companies that had explored Thai market entry have largely withdrawn or paused expansion plans. Canadian licensed producer Tilray Brands, which announced a Thai partnership in August 2023, suspended the arrangement in June 2025 citing regulatory uncertainty. U.S.-based multi-state operators including Curaleaf and Trulieve, which had conducted market research in Thailand, shifted focus to more stable international markets including Germany and Australia. **Tourism Impact**: Cannabis tourism, which had become a significant draw for international visitors, has declined sharply. Hotels and tour operators that had incorporated cannabis experiences into packages have eliminated or modified offerings. Tourism industry representatives estimate cannabis-related tourism generated $200-300 million in revenue during 2023-2024. This figure has fallen to less than $50 million under current restrictions. **Medical Market Growth**: While recreational businesses have contracted, the legitimate medical cannabis sector has expanded. The number of registered patients grew from 180,000 in early 2025 to 285,000 by September 2026. Medical dispensaries report steady demand for cannabis oil, capsules, and topical products for chronic pain, anxiety, and sleep disorders. The medical market provides a sustainable foundation for compliant operators, though at a fraction of the scale of the previous recreational market.

What Experts Say

Public health officials, industry representatives, and policy analysts offer sharply divergent assessments of Thailand's cannabis policy evolution. Dr. Surachoke Tangwiwat, director of Thailand's Department of Medical Services, has defended the regulatory tightening as necessary to protect public health. In a July 2026 interview with the Bangkok Post, Surachoke said the 2022 decriminalization created "a wild west situation" where cannabis products of unknown quality and potency were sold without medical oversight. He emphasized that the current framework maintains access for legitimate medical patients while preventing recreational abuse. Rattapon Sanrak, president of the Thai Cannabis Industry Association, has criticized the regulations as overly restrictive and economically destructive. Speaking at an industry conference in August 2026, Rattapon argued that the 0.2 percent THC limit eliminates most therapeutic applications and that the licensing system favors large operators over small businesses. He stated that thousands of entrepreneurs who invested in good faith during the legal period have lost their livelihoods. Dr. Prasitchai Nunual, a pharmacology professor at Chulalongkorn University, has studied Thailand's cannabis policy evolution. According to research published in the Journal of Cannabis Research in May 2026, Prasitchai found that the rapid liberalization without adequate regulatory preparation created predictable problems including youth access, impaired driving, and quality control failures. He recommended that other jurisdictions considering cannabis reform implement comprehensive regulations before removing criminal penalties. Niyada Esmond, a Bangkok-based attorney specializing in cannabis law, has noted that enforcement remains inconsistent across Thailand's provinces. In an interview with the Chiang Mai Times in September 2026, Niyada explained that provincial health offices interpret regulations differently, creating confusion for businesses operating in multiple locations. She called for clearer enforcement guidelines and better coordination among regulatory agencies. International observers have viewed Thailand's experience as a cautionary example. Martin Jelsma, coordinator of the Drugs & Democracy Programme at the Transnational Institute, wrote in a June 2026 analysis that Thailand's policy reversal demonstrates the political risks of cannabis reform without building public consensus. Jelsma noted that the backlash against liberalization has set back broader drug policy reform efforts in Southeast Asia.

What's Next

Thailand's cannabis policy will continue evolving through 2027 as the government refines regulations and enforcement approaches. The Ministry of Public Health has announced plans to review the Cannabis and Hemp Control Act in early 2027, one year after full implementation. The review will assess whether the 0.2 percent THC limit appropriately balances medical access with public health protection. Some medical professionals have advocated for higher THC limits for specific conditions including cancer pain and epilepsy, arguing that 0.2 percent is insufficient for therapeutic effect. Parliamentary elections scheduled for May 2027 could significantly impact cannabis policy. If the Move Forward Party or other opposition parties gain power, they may pursue stricter controls including re-criminalizing possession. Conversely, if the Bhumjaithai Party strengthens its position, it may advocate for relaxing some current restrictions. Cannabis policy has emerged as a significant electoral issue, particularly among younger voters and rural agricultural communities. The FDA plans to expand the medical cannabis patient registry and streamline prescription processes. The agency aims to register 500,000 patients by December 2027, which would represent approximately 0.7 percent of Thailand's population. Expanded patient access could provide political support for maintaining the current medical framework. International developments may influence Thai policy. If neighboring countries including Malaysia or Vietnam liberalize cannabis laws, Thailand may face pressure to remain competitive. The United Nations Commission on Narcotic Drugs' ongoing review of cannabis scheduling could also affect Thailand's approach, particularly regarding international treaty obligations under the 1961 Single Convention. Legal challenges to the Cannabis and Hemp Control Act are pending in Thai courts. Several business owners have filed constitutional challenges arguing that the regulations constitute uncompensated taking of property and violate due process. The Constitutional Court is expected to rule on these challenges in 2027. A ruling against the government could force regulatory modifications. The Thai cannabis industry is consolidating around compliant medical operators. Industry analysts expect 5-10 larger companies to dominate the legal market by 2028, with smaller operators serving niche segments or exiting entirely. This consolidation mirrors patterns observed in mature cannabis markets including Canada and several U.S. states. Research institutions are expanding cannabis studies despite regulatory uncertainty. Chulalongkorn University, Mahidol University, and Chiang Mai University have active cannabis research programs examining medical applications, agricultural optimization, and economic impacts. Research findings may inform future policy adjustments.

Further Reading

• Cannabis and Hemp Control Act B.E. 2568 (2025) - Full text available at Thailand Ministry of Public Health: http://www.moph.go.th
• Narcotics Act B.E. 2522 (1979) - Thailand Office of the Narcotics Control Board: http://www.oncb.go.th
• Thailand Food and Drug Administration Cannabis Registry - Plook Ganja application and licensing information: http://www.fda.moph.go.th
• United Nations Single Convention on Narcotic Drugs (1961) - Full treaty text: http://www.unodc.org
• "Cannabis Policy Reform in Thailand: Public Health and Economic Implications" - Journal of Cannabis Research, May 2026
• Prohibition Partners Thailand Cannabis Report 2025 - Market analysis and projections: http://www.prohibitionpartners.com
• Thai Cannabis Industry Association - Industry perspectives and advocacy: http://www.thaicannabis.org
• Transnational Institute Drugs & Democracy Programme - International drug policy analysis: http://www.tni.org